Femme Homme | 18 ans et plus
- | Pays :
- France
- | Organes :
- Sein
- | Spécialités :
- Chimiothérapie
Extrait
Prospective, Multicenter, Randomized, Independent-Group, Open-Label Phase II Study to Investigate the Efficacy, Safety and Tolerability of 4 Regimen With 3 Doses of ZK 219477 (16 and 12 mg/m<sup>2</sup> Body Surface Area as 3-Hour Infusion or 22 mg/m<sup>2</sup> Body Surface Area as 30-Minute or 3-Hour Infusion) in Patients With Metastatic Breast Cancer.
Extrait Scientifique
en cours d'intégration;